Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors

Abstract

When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment.

Keywords

• nsclc
• intercalated treatment
• egfr
• tyrosine-kinase inhibitors